New review explores why eczema and ADHD often overlap in youth, highlighting sleep loss, itch-driven inflammation, plus screening and treatment tips.
|Articles|January 1, 2003
Management beyond corticosteriods starts with assessing risk to skin, reducing sun exposure
Author(s)Rebecca Bryant
Paris - Treatment for dermatomyositis (DM) begins with sun avoidance and sun-protective measures, Jeffrey P. Callen, M.D., said at the World Congress of Dermatology. "The first line of therapy is to recognize that the patient is photosensitive."
Advertisement
Advertisement
Related to this article
LEO Pharma has closed its acquisition of dersimelagon from Tanabe Pharma after the FDA accepted the drug's NDA for filing and granted Priority Review, with a PDUFA date expected by the end of February 2027.
Sol-Gel Technologies has completed patient follow-up in its pivotal phase 3 trial of SGT-610 (patidegib gel, 2%) for Gorlin syndrome, with top-line results expected in late November 2026.
Two small clinical studies evaluated skincare and dermabrasion for changes in skin quality among individuals taking medical weight loss medications.
Two-year POETYK PsA-2 data showed sustained ACR and minimal disease activity responses with deucravacitinib and no new safety signals.
Faculty from the Cutaneous Oncology Workshop answer practical questions spanning skin cancer prevention, diagnosis, treatment, and follow-up.
Two new Neutrogena facial sunscreens incorporate bemotrizinol, the first new sunscreen active ingredient added to the US OTC monograph in decades.
Longer treatment duration was independently associated with VASI improvement, while publicly insured patients experienced higher topical JAK inhibitor denial rates.
Advertisement
Advertisement
Trending on Dermatology Times
1
Clascoterone 5% Topical Solution Shows Long-Term Promise for Male Pattern Hair Loss
2
Neutrogena Launches New Sunscreens With Newly Permitted UV Filter Bemotrizinol
3
Maui Derm NP+PA Fall 2026 Day 2: GLP-1s, Inflammatory Disease, and Diagnostic Challenges
4
Dersimelagon NDA Accepted by FDA with Priority Review for EPP, XLP
5